keyword
MENU ▼
Read by QxMD icon Read
search

Leptomeningeal carcinomatosis

keyword
https://www.readbyqxmd.com/read/28405535/signet-cell-in-the-brain-a-case-report-of-leptomeningeal-carcinomatosis-as-the-presenting-feature-of-gastric-signet-cell-cancer
#1
Saeed Ali, Muhammad Talha Khan, Evgeny A Idrisov, Aadil Maqsood, Fnu Asad-Ur-Rahman, Khalid Abusaada
Malignant infiltration of pia and arachnoid mater, referred to as leptomeningeal carcinomatosis (LMC), is a rare complication of gastric carcinoma. The most common underlying malignancy in patients with LMC are leukemia, breast cancer, lymphoma, and lung cancer. We report a case of gastric adenocarcinoma that presented with LMC in the absence of overt gastrointestinal signs or symptoms. A 56-year-old Hispanic woman presented to the hospital with a three-week history of intermittent headaches and visual blurring...
March 7, 2017: Curēus
https://www.readbyqxmd.com/read/28242978/intracranial-leptomeningeal-carcinomatosis-in-three-cases-from-breast-cancer-demonstrated-on-f-18-fluorodeoxyglucose-positron-emission-tomography-computerized-tomography
#2
Hulya Ortapamuk, Mustafa Kemal Demir
Leptomeningeal carcinomatosis (LC) is an uncommon late manifestation of non-central nervous system (CNS) solid tumors. With prolonged survival in solid tumors, an increased frequency of metastases is noted in these tumors too. The detection of tumor cells in the cerebrospinal fluid remains the gold standard. Noninvasively, magnetic resonance imaging is frequently used for the diagnosis of LC. Although its low sensitivity of F-18 fluorodeoxyglucose positron emission tomography/computerized tomography (F-18 FDG PET/CT) on demonstrating CNS lesions, it could be useful in identifying the possibility of LC of breast carcinoma by giving high attention to the meninges...
January 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28242865/metronomic-capecitabine-effectively-blocks-leptomeningeal-carcinomatosis-from-breast-cancer-a-case-report-and-literature-review
#3
REVIEW
Michela Maur, Claudia Omarini, Federico Piacentini, Annalisa Fontana, Elisa Pettorelli, Stefano Cascinu
BACKGROUND Meningeal carcinomatosis is a rare complication in breast cancer patients. At present, there are no defined guidelines for its management. The efficacy of systemic treatment seems to depend on its ability to cross the blood-brain-barrier and its interaction with tumor vasculature. Metronomic chemotherapy is a known modality of drug administration able to inhibit tumor angiogenesis. CASE REPORT We present a case of symptomatic leptomeningeal carcinomatosis from breast cancer successfully treated with capecitabine...
February 28, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28231581/prognostic-markers-and-histologic-subtypes-in-patients-with-meningeal-carcinomatosis-in-breast-cancer
#4
Hussein Alnajar, Lauren Rosen, Sara Javidiparsijani, Yahya Al-Ghamdi, Paolo Gattuso
OBJECTIVE: Meningeal carcinomatosis (MC) is a rare complication in breast cancer patients. It is defined as a diffuse or multifocal leptomeningeal metastasis. STUDY DESIGN: From our institution database, we retrospectively studied 19 patients diagnosed with MC in the cerebrospinal fluid (CSF) in 1997-2015, in order to evaluate tumor prognostic markers, histologic subtypes, and clinical outcome. RESULTS: All patients were female, with a mean age of 53 years (range 36-75 years)...
February 24, 2017: Acta Cytologica
https://www.readbyqxmd.com/read/28225456/efficacy-of-bevacizumab-and-erlotinib-combination-for-leptomeningeal-carcinomatosis-after-failure-of-erlotinib
#5
Ryo Ariyasu, Atsushi Horiike, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Yosuke Kawashima, Natsuki Takano, Tomoyo Oguri, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio
In patients with non-small-cell lung cancer harboring an epithelial growth factor receptor (EGFR) active mutation, central nervous system progression after a response to EGFR tyrosine kinase inhibitors is frequent. Central nervous system metastasis, especially leptomeningeal carcinomatosis (LMC), is a serious complication and no standard treatment has been established for LMC. Here, we report two cases in which the addition of bevacizumab to erlotinib enhanced the efficacy against LMC; as a result, radiographic abnormalities decreased markedly and symptoms were well controlled...
June 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28178712/surgical-treatment-for-leptomeningeal-disease
#6
REVIEW
Andrey A Volkov, Andreas K Filis, Frank D Vrionis
BACKGROUND: Advancements in cancer treatment have led to more cases of leptomeningeal disease, which requires a multimodal approach. METHODS: Treatment modalities are reviewed from a neurosurgical standpoint, focusing on intrathecal chemotherapy and shunting devices. Potential complications and how to avoid them are discussed. RESULTS: The Ommaya reservoir and the chemoport are used for administering intrathecal chemotherapy. Use of ventriculo-lumbar perfusion can efficiently deliver chemotherapeutic agents and improve intracerebral pressure...
January 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28149755/state-of-the-art-of-chemotherapy-for-the-treatment-of-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#7
REVIEW
Alessandro Inno, Vincenzo Di Noia, Ettore D'Argento, Alessandra Modena, Stefania Gori
Chemotherapy is the mainstay of treatment of advanced non-small cell lung cancer (NSCLC) without molecular drivers. Despite a low penetration of central nervous system (CNS), chemotherapy drugs demonstrated encouraging activity against CNS metastases from NSCLC. Based on the available data, chemotherapy should be considered as an important part of the multidisciplinary treatment of CNS metastases. Particularly, platinum-based regimens represent the most active combinations and pemetrexed is associated with a meaningful clinical benefit for patients with non-squamous histology...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28138027/met-copy-number-gain-is-associated-with-gefitinib-resistance-in-leptomeningeal-carcinomatosis-of-egfr-mutant-lung-cancer
#8
Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano
Leptomeningeal carcinomatosis (LMC) occurs frequently in EGFR-mutant lung cancer, and develops acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This study aimed to clarify the mechanism of EGFR-TKI resistance in LMC and seek for a novel therapeutic strategy. We examined EGFR mutations, including the T790M gatekeeper mutation, in 32 re-biopsy specimens from 12 LMC and 20 extracranial lesions of EGFR-mutant lung cancer patients who became refractory to EGFR-TKI treatment. All the 32 specimens had the same baseline EGFR mutations, but the T790M mutation was less frequent in LMC specimens than in extracranial specimens (8% vs...
January 30, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28110254/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-patients-a-continuing-challenge-in-the-personalized-treatment-era
#9
REVIEW
J Remon, E Le Rhun, B Besse
Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer patients and up to 5% and 9% in ALK-rearranged and EGFR-mutant lung cancer patients, respectively. The prognosis remains poor despite systemic treatment, intrathecal chemotherapy, radiation therapy and personalized treatments in molecularly selected patients. However, new therapies with improved cerebral-spinal fluid penetration have been developed for subgroups of molecular selected patients indicating they could be promising therapeutic options for managing leptomeningeal disease...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28101027/bilateral-facial-nerve-paralysis-as-first-presentation-of-lung-cancer
#10
Shadi Hamouri, Duha Al Shorafat
Leptomeningeal carcinomatosis is rare, and its precise incidence is unknown. It is associated with a wide spectrum of solid and hematological malignancies. To complicate its diagnosis, the clinical presentation of leptomeningeal carcinomatosis can be variable. We report a case of a 38-year-old male with bilateral facial nerve paralysis as first presentation of lung adenocarcinoma. To our knowledge, this is the only case describing bilateral facial nerve palsy as the first and only manifestation of lung adenocarcinoma...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/28064206/retrospective-analysis-of-survival-in-patients-with-leptomeningeal-carcinomatosis-from-lung-adenocarcinoma-treated-with-erlotinib-and-gefitinib
#11
Jumpei Kashima, Yusuke Okuma, Maki Miwa, Yukio Hosomi
Background: Leptomeningeal carcinomatosis is a relatively rare metastatic form of non-small cell lung cancer, which can impact prognosis. There is an increasing need for selecting suitable epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among those currently included in standard care for EGFR mutation-positive patients. We compared the efficacy of gefitinib and erlotinib in survival of patients with leptomeningeal carcinomatosis. Patients and methods: The medical records of 269 patients who received tyrosine kinase inhibitors at a single center were retrospectively reviewed...
April 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28030859/clinical-efficacy-of-afatinib-treatment-for-a-patient-with-leptomeningeal-carcinomatosis
#12
Yo Kawaguchi, Jun Hanaoka, Hideki Hayashi, Naoki Mizusaki, Hirotoshi Iihara, Yoshinori Itoh, Tadashi Sugiyama
Leptomeningeal metastases occur in 1% of patients with non-small-cell lung cancer. There have been several reports on the treatment of leptomeningeal metastases with afatinib. Our patient was a 41-year-old woman who had never smoked and was diagnosed with stage IV adenocarcinoma of the lung with an epidermal growth factor receptor (EGFR) mutation. She was treated with afatinib for the recurrence of leptomeningeal metastases. After the treatment with afatinib was initiated, the neurological symptoms dramatically regressed, and she achieved progression-free survival for 7 months...
2017: Chemotherapy
https://www.readbyqxmd.com/read/27914156/-intratechal-chemotherapy-treatment-through-an-ommaya-reservoir-catheter-for-meningeal-carcinomatosis-a-single-centre-experience
#13
José Pedro Lavrador, Nuno Simas, Edson Oliveira, Manuel Herculano Carvalho
INTRODUCTION: Meningeal carcinomatosis is defined as tumour cells infiltration of leptomeninges and subarachnoid space. It is normally related with poor survival (2 - 5 months). The best multidisciplinary treatment for this condition is a matter of discussion. Patient's condition and the natural history of the disease should be considered in the decision making process. MATERIAL AND METHODS: Retrospective cohort analysis of patients submitted to Ommaya Reservoir placement due to systemic solid tumour meningeal carcinomatosis between 2006 and 2014...
August 2016: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/27854097/optimizing-the-delivery-of-antineoplastic-therapies-to-the-central-nervous-system
#14
REVIEW
Jarushka Naidoo, Hardik Panday, Sadhana Jackson, Stuart A Grossman
Despite significant advances in the treatment of systemic cancers, progress in the treatment of primary brain tumors has been quite modest. In addition, an increasing proportion of patients with systemic cancers are presenting with brain-only metastases. These observations highlight the critical role that the blood-brain barrier plays in preventing antineoplastic therapies from reaching the central nervous system in therapeutic concentrations. This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27847569/retrospective-analysis-of-cerebrospinal-fluid-profiles-in-228-patients-with-leptomeningeal-carcinomatosis-differences-according-to-the-sampling-site-symptoms-and-systemic-factors
#15
Youngbo Shim, Ho-Shin Gwak, Sohee Kim, Jungnam Joo, Sang-Hoon Shin, Heon Yoo
OBJECTIVE: Elevated cell counts and protein levels in cerebrospinal fluid (CSF) result from disease activity in patients with leptomeningeal carcinomatosis (LMC). Previous studies evaluated the use of CSF profiles to monitor a treatment response or predict prognosis. CSF profiles vary, however, according to the sampling site and the patient's systemic condition. We compared lumbar and ventricular CSF profiles collected before intraventricular chemotherapy for LMC and evaluated the association of these profiles with patients' systemic factors and LMC disease activity...
November 2016: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/27817234/-effective-systemic-palliative-chemotherapy-for-intracranial-metastases-of-breast-cancer
#16
István Sipőcz, Tamás Pintér, Zoltán Skaliczky, Tamás Kullmann
The authors present the history of two patients. The first patient, a 69-year-old woman was diagnosed with locally invasive triple negative breast cancer with pulmonary and cerebral metastases. Complete radiological remission of the clinically asymptomatic cerebral metastases was detected under systemic chemotherapy with carboplatin-docetaxel (75 mg/m(2)). Later, the patient received whole brain radiotherapy and a second line of chemotherapy. The overall survival was 20 months from the diagnosis of cerebral metastases with conservation of partial autonomy...
November 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27809457/effects-of-postoperative-radiotherapy-on-leptomeningeal-carcinomatosis-or-dural-metastasis-after-resection-of-brain-metastases-in-breast-cancer-patients
#17
Boram Ha, Seung Yeun Chung, Yeon-Joo Kim, Ho-Shin Gwak, Jong Hee Chang, Sang Hyun Lee, In Hae Park, Keun Seok Lee, Seeyoun Lee, Tae Hyun Kim, Dae Yong Kim, Seok-Gu Kang, Chang-Ok Suh
Purpose: In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods: Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015...
October 31, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27790117/rapid-response-to-high-dose-pulsatile-erlotinib-in-afatinib-refractory-leptomeningeal-carcinomatosis-from-adenocarcinoma-of-the-lung-a-case-report
#18
Frank S Fan
Leptomeningeal carcinomatosis occurred in an old female patient who was on a standard dose of afatinib for the treatment of her non-small cell lung cancer harboring an epidermal growth factor receptor gene mutation sensitive to tyrosine kinase inhibitors when extracranial lesions were still under control. Shifting to high-dose, pulsatile erlotinib dramatically saved her from the devastating condition in a very short period of time. Inadequate afatinib concentration in cerebrospinal fluid is reasonably suspected, and there is a call for clinical trials testing high-dose afatinib in leptomeningeal carcinomatosis...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27721269/prolonged-overall-survival-of-patients-with-leptomeningeal-carcinomatosis-from-nonsmall-cell-lung-cancer
#19
LETTER
Yanfang Ju, Shengjie Sun, Jinliang Wang, Shunchang Jiao
Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27688614/intrathecal-trastuzumab-for-leptomeningeal-carcinomatosis-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#20
Seema Gulia, Sudeep Gupta, Ashish Singh
There has been recent increase in incidence of leptomeningeal carcinomatosis, possibly due to widespread use of adjuvant trastuzumab and its known poor CNS penetration. Currently there are limited therapeutic options for these patients and outcome is poor. We report two cases of women with HER2 positive breast cancer who developed leptomeningeal carcinomatosis for which they were treated with intrathecal trastuzumab in combination with systemic therapy. Both patients had rapid symptomatic benefit and radiological response and remained progression free for at least seven months...
July 2016: Indian Journal of Medical and Paediatric Oncology
keyword
keyword
71957
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"